Ticagrelor
Composition
The formulation contains Ticagrelor 90 mg with mannitol, microcrystalline cellulose, calcium hydrogen phosphate, sodium starch glycolate, magnesium stearate, hypromellose, titanium dioxide, and polyethylene glycol as the active ingredient.
Indications
Indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or history of myocardial infarction.
Side effects
Common side effects include bleeding, dyspnea (shortness of breath), headaches, dizziness, and increased uric acid levels.
Precautions
To be used with caution in patients with a history of bleeding disorders or undergoing surgery.
Contraindications
Contraindicated in patients with active bleeding or a history of intracranial hemorrhage.
Dosage and administration
The recommended loading dose is 180 mg orally, followed by 90 mg twice daily.
Countries
Available globally.
Available Forms
Tablets
Manufacturing Services
Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai